31 March 2025NewsEuropeMarisa Woutersen

‘Always new twists’: Bayer legal team on defending a $4bn drug

With billions in revenue at stake, the pharma giant has a 27-country parallel litigation effort to protect its blockbuster blood thinner from generics. Marisa Woutersen finds Bayer’s outside litigation counsel ready for anything.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Bayer granted 10-day injunction in blood clot drug dispute

28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.

EPO upholds Bayer's Xarelto dosage patents

4 November 2021 Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office, the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto.

More on this story

Bayer granted 10-day injunction in blood clot drug dispute

28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.

EPO upholds Bayer's Xarelto dosage patents

4 November 2021 Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office, the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto.

More on this story

Bayer granted 10-day injunction in blood clot drug dispute

28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.

EPO upholds Bayer's Xarelto dosage patents

4 November 2021 Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office, the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto.

More features

Patent cliff: 5 blockbusters running out of road

Herbert Smith Freehills expands German tech patent team

Novartis and MSN feud intensifies after Fed Circ denies rehearing

EU court signals tough stance on ‘pay-for-delay’ pharma deals

Panitch Schwarze hires experienced ex-USPTO examiner

Fed Circ affirms generic’s litigation costs of $12m are tax-deductible

Genmab fights claim over 'secrets theft' behind $1.8bn takeover

Interpreting the SPC manufacturing waiver: EU courts diverge